In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Wins Japanese Approval For Cervarix As First Cervical Cancer Vaccine In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - GlaxoSmithKline K.K., the fully-owned Japanese subsidiary of GlaxoSmithKline, has won Japan's Ministry of Health, Labor and Welfare approval for cervical cancer vaccine Cervarix, the first cervical cancer vaccine to be marketed in Japan, the company announced Oct. 16

You may also be interested in...



GSK Names Former Sanofi Executive As President Of Japanese Affiliate

GlaxoSmithKline has appointed Philippe Fauchet, formerly a senior vice president at Sanofi-Aventis, as the new president of GSK's Japanese subsidiary

GSK Names Former Sanofi Executive As President Of Japanese Affiliate

GlaxoSmithKline has appointed Philippe Fauchet, formerly a senior vice president at Sanofi-Aventis, as the new president of GSK's Japanese subsidiary

GSK Files Japan's First Rotavirus Vaccine; Will Japan Become Next Battleground For Vaccine Makers?

GlaxoSmithKline announced Nov. 30 it is applying for approval for its rotavirus vaccine Rotarix with Japan's Ministry of Health, Labor and Welfare. If approved, it will become the first vaccine in Japan to prevent rotavirus gastroenteritis, a leading cause of diarrhea-related deaths in children

Related Content

UsernamePublicRestriction

Register

SC070134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel